Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$6.50
$7.70
50-Day Range
N/A
52-Week Range
N/A
Volume
75,793 shs
Average Volume
57,512 shs
Market Capitalization
$82.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 608th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elicio Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elicio Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elicio Therapeutics has a P/B Ratio of 4.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.55% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 45.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.55% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 45.38%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Elicio Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

  • Read more about Elicio Therapeutics' insider trading history.
Receive ELTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELTX Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Elicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last year
See More Headlines

ELTX Stock Analysis - Frequently Asked Questions

Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.20.

Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Top institutional shareholders of Elicio Therapeutics include CM Management LLC (0.51%), Royal Bank of Canada (0.34%), Jane Street Group LLC (0.14%) and Moody Lynn & Lieberson LLC (0.09%).
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/13/2025
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+30.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.19 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Book Value
$1.35 per share
Price / Book
5.70

Miscellaneous

Free Float
7,699,000
Market Cap
$82.98 million
Optionable
Not Optionable
Beta
0.77
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:ELTX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners